JP2010536837A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536837A5
JP2010536837A5 JP2010521478A JP2010521478A JP2010536837A5 JP 2010536837 A5 JP2010536837 A5 JP 2010536837A5 JP 2010521478 A JP2010521478 A JP 2010521478A JP 2010521478 A JP2010521478 A JP 2010521478A JP 2010536837 A5 JP2010536837 A5 JP 2010536837A5
Authority
JP
Japan
Prior art keywords
taxane
composition according
pvp
composition
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536837A (ja
JP5404625B2 (ja
Filing date
Publication date
Priority claimed from GB0716591A external-priority patent/GB0716591D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Publication of JP2010536837A publication Critical patent/JP2010536837A/ja
Publication of JP2010536837A5 publication Critical patent/JP2010536837A5/ja
Application granted granted Critical
Publication of JP5404625B2 publication Critical patent/JP5404625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521478A 2007-08-24 2008-08-22 組成物 Active JP5404625B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
GB0716591.3 2007-08-24
US60/957,764 2007-08-24
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (3)

Publication Number Publication Date
JP2010536837A JP2010536837A (ja) 2010-12-02
JP2010536837A5 true JP2010536837A5 (enExample) 2012-10-18
JP5404625B2 JP5404625B2 (ja) 2014-02-05

Family

ID=38599259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521478A Active JP5404625B2 (ja) 2007-08-24 2008-08-22 組成物

Country Status (5)

Country Link
JP (1) JP5404625B2 (enExample)
CN (1) CN101854919B (enExample)
ES (1) ES2535401T3 (enExample)
GB (1) GB0716591D0 (enExample)
RU (1) RU2488384C2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
JP7317804B2 (ja) 2017-09-07 2023-07-31 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド ドセタキセル結合体の医薬組成物及び調製方法
PE20220250A1 (es) 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
PE20220129A1 (es) * 2018-12-21 2022-01-27 Modra Pharmaceuticals B V Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180020B2 (en) * 1999-05-27 2009-06-24 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Similar Documents

Publication Publication Date Title
US20230138361A1 (en) Enhanced delivery epinephrine compositions
JP2010536837A5 (enExample)
JP2011037876A5 (enExample)
EP3085357B1 (en) Microneedle
US20170290776A1 (en) Pharmaceutical compositions with enhanced permeation
JP2009530415A5 (enExample)
JP2010510241A5 (enExample)
US12433850B2 (en) Enhanced delivery epinephrine and prodrug compositions
JP2024012484A (ja) 増強された透過を有する医薬組成物
RU2488384C2 (ru) Композиции для лечения неопластических заболеваний
CN104902905A (zh) 药物组合物
CN103705494A (zh) 一种胰岛素纳米透皮贴剂及其制备方法
IL313551A (en) Enhanced delivery epinephrine and prodrug compositions
CN104352482A (zh) 膜组合物
US20180200198A1 (en) Pharmaceutical compositions with enhanced permeation
US20250108017A1 (en) Enhanced delivery epinephrine and prodrug compositions
US20190022022A1 (en) Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) Enhanced delivery epinephrine compositions
JP2012500788A5 (enExample)
RU2012101817A (ru) Композиции олмесартана медоксомила в форме наночастиц, способ их получения и содержащие их фармацевтические композиции
US20180125977A1 (en) Enhanced delivery epinephrine compositions
JP2011509925A (ja) タキサン誘導体を含有する、改良された再構成時間を有する凍結乾燥医薬組成物及びその製法
JP2006524190A5 (enExample)
US11260024B2 (en) Polymeric compositions containing ambient-temperature stable biopharmaceuticals and methods for formulation thereof
WO2024220974A1 (en) Rimegepant fast-dissolving films for oral administration